Tandem Diabetes Care Inc(TNDM)stock report

Tandem Diabetes Care, Inc. is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim X2 Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). Its technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism. It also features a software, which is a vivid color touch screen and a micro- universal serial bus (USB) connection that supports both a rechargeable battery and uploads to t:connect Diabetes Management Application (t:connect), its custom cloud-based data management application that provides display therapy management data from the pump and supported blood glucose meters.

Finance:
Market Cap:4100M; Shares Outstanding:59.1M; Short Interest: 12.79%; Q3 2019(9/30/19): Cash 157M Loss 2.91M

EPS and Sales:
https://finance.yahoo.com/quote/TNDM/financials?p=TNDM

Date EPS % last year % last quarter
2018.12.31 -2.14 70.39% 23.84%
2019.3.31 -0.4 78.02% 81.31%
2019.6.30 -0.42 75.62% -5.00%
2019.9.30 -0.47 83.27% -11.90%

 

Date Sales % last year % last quarter
2018.12.31 184M 70.88% 70.37%
2019.3.31 66M 141.94% -64.13%
2019.6.30 159M 159.36% 140.91%
2019.9.30 254M 135.83% 59.75%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=TNDM&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/TNDM/institutional-ownership/

2020.01.23:
Total institutions: 306,no change
Shares hold: 49816.2k shares. Reduced 0.61K
shares% hold: 84.3%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/TNDM/price-targe

*News:
2020.01.17: Tandem Diabetes Care Inc (TNDM) EVP & CHIEF COMMERCIAL OFFICER Brian B Hansen Sold $697,600 of Shares

2020.01.15: Tandem Diabetes Care Announces Commercial Launch of the t:slim X2 Insulin Pump with Control-IQ Technology in the United States

2019.12.26: Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry

2019.12.13: FDA authorizes first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customize their individual diabetes management device system

2019.11.08: Tandem Diabetes down 6% on death of t:slim X2 user

2019.11.04: Tandem Diabetes Care Announces Third Quarter 2019 Financial Results and Updated 2019 Financial Guidance

2019.10.15: Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management

Leave a Reply